rttnews.comSEP 72 min read$MTNB

Matinas BioPharma Receives NYSE American Non-Compliance Notice

Matinas BioPharma (MTNB) received a non-compliance notice from NYSE American due to stockholders' equity below $2M. The company has until October 2, 2027, to regain compliance. MTNB's stock closed at $0.18 on Friday, up 0.55%. The company's lead drug candidate is MAT2203, an antifungal treatment.

Original reporting

rttnews.com

Published Sep 7, 2026, 5:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 7, 2026, 6:31 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefCorporate actions

Primary signal

$MTNB

Bearish

high confidence

Mentioned

$MTNB

Relevance

6/10

AlphAI data visualization · based on rttnews.com

Decision brief

The 30-second read

$MTNBBearishLow

Why it matters

The notice signals heightened regulatory scrutiny and possible delisting, pressuring the share price.

Market read

Compliance risk for a micro‑cap biotech could trigger a sell‑off and affect peer valuations.

What to watch

Potential for a reverse split or private placement that may stabilize equity levels.

Relevance 6/10Novelty 7/10Timing: today

Background

NYSE American requires $2 million equity for companies with recent losses; MTNB fell short at $1.8 million.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MTNBBearishHigh confidence

Context

Matinas BioPharma received a NYSE American notice of non‑compliance with equity requirements, risking delisting.

Expected impact

Downside risk of 10‑15% if compliance is not achieved by the deadline.

Evidence & confidence

Compliance failures for micro‑caps often lead to sharp price declines as investors price in delisting risk.

Market effects

Sector

Highlights compliance risk for other small biotech listings on NYSE American.

Regional

Limited to U.S. micro‑cap biotech segment.

Global

Minimal global impact.

Counterpoint

What could challenge this read

If the company secures a capital raise quickly, the compliance notice could be a short‑term catalyst for a bounce.

Key entities

company
Matinas BioPharma Holdings, Inc.
Biopharmaceutical firm listed under ticker MTNB.
exchange
NYSE American
Exchange that issued the non‑compliance notice.

Read at source ← All news

JUL 18

$NVSMedAI 8/10

Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data

Healthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.

rttnews.com7 min

JUL 14

$MTNBMedAI 9/10

Matinas BioPharma To Merge With GH Power; Sells LNC Platform And MAT2203 To Azurity Pharmaceuticals

Matinas BioPharma (MTNB) will merge with GH Power Inc. to form GH Power International, a NYSE-listed clean energy and green hydrogen company, under a definitive agreement. Matinas also agreed to sell its LNC platform and lead antifungal MAT2203 to Azurity Pharmaceuticals for $4M upfront, up to $17.5M milestones, and mid-single-digit royalties.

rttnews.com5 min

JUL 13

$MTNBMed

GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma

GH Power Inc. said it agreed to combine with Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) in a deal expected to create a NYSE-listed clean energy and critical minerals company. GH Power’s modular reactor tech would be scaled for hydrogen, heat, power, and alumina. A PIPE of at least $15.0M is planned, and the deal is expected to close in Q4 2026.

thestarphoenix.com5 min

JUN 26

$MTNBMed

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

Matinas BioPharma (NYSE American: MTNB) said it received a June 24, 2026 NYSE American notice for non-compliance with continued listing equity standards. The company reported stockholders’ equity of $3.02 million as of March 31, 2026 and losses in five of its last fiscal years, and previously $4.83 million as of Dec. 31, 2025. NYSE American accepted its May 4, 2026 compliance plan, granting a plan period through Oct. 2, 2027, with quarterly monitoring; delisting proceedings could follow if progr

manilatimes.net4 min

SEP 20

$CLFMedAI 8/10

How Investors Are Reacting To Cliffs Stock $1b Plant Upgrade

Cleveland-Cliffs announced a $1b modernization of its Middletown Works plant, supported by a $500m U.S. Department of Energy grant. The upgrade aims to improve efficiency and sustainability. The company reported a $866.0m loss and forecasts revenue growth of 6.6% annually, with earnings expected to improve to $1.1b by 2029. Analysts have set price targets ranging from $10.0 to $15.0, with a consensus target of $12.0.

simplywall.st3 min